Newsbenzinga
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
· Published
Article summary
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.
An excerpt from the original article.
Comments —
Loading comments…